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The human Ul and U6 genes have similar basal promoter
structures. A first analysis of the factor requirements for
the transcription of a human Ul gene by RNA
polymerase H in vitro has been undertaken, and these
requirements compared with those of human U6 gene
transcription by RNA polymerase m in the same
extracts. Fractions containing PSE-binding protein (PBP)
are shown to be essential for transcription of both genes,
and further evidence that PBP itself is required for Ul
as well as U6 transcription is presented. On the other
hand, the two genes have distinct requirements for
TATA-binding protein (TBP). On the basis of chromato-
graphic and functional properties, the TBP, or TBP
complex, required for Ul transcription appears to differ
from previously described complexes required for RNA
polymerase I, H or [II transcription. The different TBP
requirements of the Ul and U6 promoters are reflected
by specific association with either TFLlB or TFLMB
respectively, thus providing a basis for differential RNA
polymerase selection.
Key words: human Ul transcription/PSE-binding protein
(PBP)/RNA polymerase/small nuclear (sn) RNA genes/
TATA-binding protein (TBP)
Introduction
The spliceosomal U snRNAs U 1, U2, U4, U5 and U6 form
a functionally related and highly conserved family in
eukaryotes. In contrast, the promoters of their genes are quite
divergent between species and, in addition, U snRNA
promoters in most species display unusual features (Dahlberg
and Lund, 1988; Simmen et al., 1992a; Bernuds et al.,
1992). Vertebrate U snRNA promoters contain a distal
sequence element (DSE) located - 250 bp upstream of the
initiation site which functions like an enhancer, and a
proximal region, including an essential proximal sequence
element (PSE) located - 50 bp from the initiation site. The
PSE functions in start site positioning and is required for
accurate 3' end formation. A promoter with only these
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elements, like those of the U 1 or U2 genes, is transcribed
by RNA polymerase II (pol II). The U6 gene, which is
transcribed by RNA polymerase Ill (pol IH), has in addition
to the DSE and PSE an essential TATA box located between
the PSE and the start site (reviewed by Dahlberg and Lund,
1988; Parry et al., 1989; Bernues et al., 1992).
The finding of an essential TATA element in the U6 and
related pol HI promoters was of interest since the TATA
box had, until then, been considered the main determinant
of pol II transcription in a major class of pol II promoters.
The first stable interaction between a transcription factor and
such a basal pol II promoter is the binding of transcription
factor TFIID to the TATA box. All the subsequent
interactions required to assemble a functional transcription
complex depend on this initial step (Buratowski et al., 1989;
Roeder, 1991 and references therein). TBP, the protein
directly responsible for binding the TATA box, has been
cloned from several organisms. At least in vertebrates and
insects TBP has been found to be only one component of
one or more multiprotein TFIID complexes (Cavallini et al.,
1989; Hahn et al., 1989; Horikoshi et al., 1989; Schmidt
et al., 1989; Fikes et al., 1990; Gasch et al., 1990; Hoey
et al., 1990; Hoffmann et al., 1990a,b; Kao et al., 1990;
Muhich et al., 1990; Peterson et al., 1990; Dynlacht et al.,
1991; Pugh and Tjian, 1991; Timmers and Sharp, 1991).
In this paper we will follow the nomenclature suggested by
Dynlacht et al. (1991) who called the cloned protein TBP
(for TATA-binding protein) and referred to the complex(es)
involved in pol II transcription as TFIID. The work of
Timmers and Sharp (1991) suggested that two such
complexes exist, called B-TFIID and D-TFIID, which differ
in their composition and chromatographic behaviour.
In vivo experiments in which promoter sequences were
swapped between vertebrate U6 and U2 genes showed that
insertion of a U6 TATA box into a U2 promoter conferred
pol HI specificity, whereas removal of the U6 TATA box
abolished pol III transcription, but allowed pol II transcription
from the mutant U6 promoter (Mattaj et al., 1988; Lobo
and Hernandez, 1989). More recently, Lescure et al. (1991)
have shown that insertion of a TATA box into a Xenopus
Ul promoter conferred pol Im specificity, reinforcing the
correlation between the presence of a TATA box and the
use of pol HI for U snRNA genes. This apparent paradox
was underlined by the demonstration that transcription of
a human U6 gene by pol Im in vitro required TBP (Lobo
et al., 1991; Simmen et al., 1991). The simplest hypothesis
to explain polymerase choice in U snRNA promoters at that
time was that a PSE-binding factor on its own would select
pol II without the involvement of TBP whereas the PSE
factor in conjunction with a TATA-bound TBP complex
would select pol HII.
From other studies, however, it has become clear that TBP
plays a general role in transcription. It is a component of
TFIIIB, required for the transcription of all pol Im promoters,
including those of Saccharomyces cerevisiae U6 or of tRNA
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or 5S ribosomal RNA genes, whose structures are different
from those of vertebrate U6 promoters (Margottin et al.,
1991; Huet and Sentenac, 1992; Kassavetis et al., 1992;
Lobo et al., 1992; Simmen et al., 1992b; Taggart et al.,
1992; White et al., 1992; White and Jackson, 1992). TBP
is also a component of SLI, which is necessary for
transcription from pol I promoters (Comai et al., 1992). In
addition, TBP complexes have been shown to function in
the pol II transcription of two similar (artificial) TATA-less
promoters (Smale et al., 1990; Pugh and Tjian, 1990, 1991;
Zhou et al., 1992).
It therefore became likely that TBP would be required for
the transcription of the pol II class of U snRNA genes and
the simple model of polymerase choice presented above
became improbable. In order to gain more insight into the
requirements for transcription of the two U snRNA gene
classes, we have undertaken an in vitro biochemical analysis
of Ul and U6 transcription in nuclear extracts of HeLa cells.
Our data are consistent with the hypothesis that pol II and
pol III U snRNA promoters utilize a common PSE-binding
factor but different TBP complexes. This primary difference
would then result in selection of alternative basal transcription
factors, TFIIB and TFIIB respectively, and in differential
RNA polymerase choice.
Results
Transcription of human U1 requires TBP and at least
one other heat-labile factor
The only available large-scale in vitro transcription system
capable of accurate transcription of pol II U snRNA genes
is that described by Gunderson et al. (1990). Utilizing the
same human Ul promoter G-less cassette fusion construct
and slight modifications to the procedure for preparing HeLa
cell nuclear extract (see Materials and methods) we have
been able to achieve a considerable (> 10-fold) increase in
U1 transcription efficiency per microgram of nuclear extract
(data not shown, Figure lA, lane 1).
Two RNA products were obtained on transcription of the
human Ul template (Figure 1A, lane 1) and their structure
was investigated. The major primer extension product in the
Ul transcription reaction (Figure IB, lane 3) corresponded
to transcripts initiated at + 1, as determined by comparison
with both the sequencing reactions run in parallel and by
comigration with the primer extension product of transcripts
of a template consisting of the promoter of the human
transferrin receptor (HTFR) gene fused to a G-less cassette
(lane 2). This HTFR construct was designed to initiate at
the same nucleotide as accurate human U1 transcripts
(Gunderson et al., 1990). The longer extension product was
five nucleotides longer, and comigrated with a product
derived from an adenovirus major late (AdML) promoter
G-less cassette fusion whose transcripts are extended by five
bases at the 5' end by comparison with those from the Ul
construct. This is the length expected for read-through
products arising from non-specific transcription initiated
upstream of the promoter after their cleavage by RNase T 1.
Thus, the Ul in vitro transcription obtained was not only
more efficient but also more accurate than that seen by
Gunderson et al. (1990) since initiation from the Ul
promoter template at position -2 was not observed.
To obtain an initial indication of whether TBP was
involved in human Ul transcription, recombinant human
TBP (2.5 ng) was added to a transcription reaction(Figure lA, lane 2). A 5-fold increase in transcription was
observed, suggesting that TBP might indeed play a role in
Ul transcription. Both basal and TBP-stimulated
transcription were authentic as judged by sensitivity to 0.2
yg/ml a-amanitin (Figure IA, lanes 3 and 4) and to point
mutations in the PSE (lanes 5 and 6).
An experimentally useful property ofTBP complexes that
function in pol II and pol IIl transcription is their heat lability.
Heating nuclear extracts to 47°C for 15 min inactivates these
TBP complexes while leaving many other transcriptional
components intact (Nakajima et al., 1988; Simmen et al.,
1991; White et al., 1992). We therefore tested whether Ul
transcription required heat-labile components. After
incubation of the HeLa nuclear extract at 47°C for 15 min,
Ul transcription was abolished. However, TBP addition
alone did not restore transcription (see e.g. Figure ID,
lane 1). Simmen et al. (1991) had previously observed that,
in the case of U6 transcription, at least two heat-labile
components were required to restore activity to a heat-treated
extract. One of these components bound to phosphocellulose(PC) and was eluted at between 0.35 and 0.6 M KCl. We
therefore fractionated some of the HeLa nuclear extract over
PC into the conventional (Segall et al., 1980) A, B, C and
D fractions and tested the fractions for their ability to restore
Ul transcription to a heat-treated extract.
The AdML promoter was used as a control. As expected(Nakajima et al., 1988) the PC D fraction, which contains
D-TFIID, was sufficient to restore transcription to a heat-
treated extract, while the A, B and C fractions were inactive(Figure 1C, lanes 9-12). When the same fractions were
tested with the human Ul template, the A and B fractions
had no effect (Figure 1C, lanes 1 and 2). The D fraction
increased read-through transcription, but did not augment
authentic Ul transcription (lane 4). The C fraction, in
constrast, allowed a low level of Ul transcription (lane 3).
When the fractions were tested together with 2.5 ng of
recombinant human (h)TBP, a high level of transcription was
obtained by combining the C fraction with hTBP (lanes
5-8). Incubation of the C fraction at 47°C for 15 min
abolished this effect (data not shown). Thus, as in the case
of U6 (Simmen et al., 1991) it appears that efficient Ul
transcription requires two heat-labile components, one is
TBP and the other is present in the PC C fraction. Note
however that, in contrast to the U6 case, the C fraction alone
can restore some U1 transcription.
Both Ul and U6 transcription require PSE-binding
protein fractions
We wished to investigate this second heat-labile component
further and, in particular, to determine whether Ul and U6
require similar or different factors from the C fraction.
Initially, the PC C fraction was chromatographed over
heparin-Sepharose. Step elution at 100 (FT fraction), 250
and 500 mM KCI was carried out, and the fractions will
be referred to as Hep 100, Hep250 and Hep5OG. They were
tested for their ability to restore transcription in heat-treated
HeLa nuclear extract in the presence of hTBP. Virtually all
the activity was found in Hep500 (Figure ID, lanes 1-5).
The transcription observed was sensitive to 0.2 atg/ml ce-
amanitin (lanes 6-10).
We next turned our attention to U6. In our experiments
fractionation of HeLa cell nuclear extracts active in U6
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Fig. 1. Heat-labile components required for human Ul transcription in vitro. (A) In vitro transcription of a human U1 promoter G-less cassette
template (hUlG-) using HeLa cell nuclear extract. In vitro transcription of hUIG- (lanes 1-4) was assayed without (lanes 1 and 3) or with the
addition of 2.5 ng of recombinant full-length hTBP (lanes 2 and 4). The assays in lanes 3 and 4 were done in the presence of 0.2 Lg/Iml of c-
amanitin. An hUl PSE mutant template (containing a CC-TT double point mutation previously shown to render it inactive both in vivo and in
vitro; Gunderson et al., 1990) was assayed on its own (lane 5) or with the addition of 2.5 ng hTBP (lane 6). Correctly initiated (+ 1) and read-
through (RT) transcripts from the hU templates are indicated. Note that in this and the other transcription experiments shown in this paper an
internal standard for recovery was used, but has been cut from the figures to save space. Only experiments where sample recovery was uniform are
shown. (B) Primer extension analysis of the transcripts produced by in vitro transcription in crude HeLa cell nuclear extracts from the wild-type
human UIG- template (lane 3) in comparison with those arising from AdML promoter and human transferrin receptor (HTFR) promoter G-less
cassette templates (lanes 1 and 2 respectively) of known structure (Gunderson et al., 1990). DNA sequencing reactions obtained using the same
primer with the human Ul template DNA are also shown on the left. (C) Heat-treated (47°C for 15 min) HeLa nuclear extract was tested for its
ability to support human Ul (lanes 1-8) and AdML transcription (lanes 9-12) in combination with 3 Al of one of four PC fractions (A, B, C and
D) as indicated. Additionally, lanes 5-8 received 2.5 ng of recombinant full-length hTBP. The position of hUl read-through (RT) and correctly
initiated transcripts is indicated on the left; correctly initiated AdML transcripts are indicated on the right. M: DNA size markers. (D) The ability of
the PC C fraction (3 A1, lanes 2 and 7) and the heparin-Sepharose fractions derived from it (3 1l, lanes 3-5 and 8-10) to support hUl
transcription in heat-treated (47°C, 15 min) HeLa cell nuclear extract. All lanes additionally contain 2.5 ng of recombinant full-length hTBP. Lanes
6-10 also contained 0.2 /ig/ml of ca-amanitin. The position of read-through (RT) and correctly initiated transcripts (+1) is indicated. M: DNA size
markers.
transcription reproducibly led to a considerable loss of
activity. Recombining all the PC fractions (A, B, C and D)
generated very weak transcription independent of the relative
amounts of the fractions used. Only the addition of
recombinant TBP to this mixture restored activity to the level
seen in complete extract (Figure 2A, lanes 1 and 2, and data
not shown). This was not due to the loss of enhancer effects,
since the same phenomenon was observed using templates
from which the DSE had been deleted (data not shown). In
the presence of recombinant hTBP, lack of fractions A, B
or C caused a significant drop in transcription while lack
of fraction D had no effect (Figure 2A, lanes 3-6).
To compare the behaviour of the factor in fraction C
required for U6 transcription with that of the Ul factor
described above, we examined the ability of the
heparin-Sepharose fractions used in Figure 1D to
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Fig. 2. Requirements of a human U6 gene promoter after extract fractionation. (A) In vitro transcription reactions were carried out using a human
U6 maxigene template and 3 i1 of the PC fractions (A-D) indicated by a +. Lanes 2-6 additionally received 2.5 ng of recombinant hTBP; lane 1
received buffer. All reactions were performed in the presence of 2 /Ag/ml of a-amanitin. The position of U6 transcripts is indicated. (B)
Reconstitution of human U6 transcription. Reactions containing the PC A and B fractions (3 Ll each) and 2.5 ng of recombinant hTBP were
complemented either with PC fraction C (2 ,tl; lane 2) or the heparin-Sepharose fractions derived from it (3 or 5 1l of 100 mM KCl eluate, lanes 3
and 4; 3 or 5 Id of 250 mM KCl eluate, lanes 5 and 6; 3 or 5 1l of 500 mM KCl eluate, lanes 7 and 8). Lane 1 received buffer. The position of
U6 maxigene transcripts is indicated. (C) The same heparin-Sepharose fractions used in (B) were used, in combination with PC B fraction, to
reconstitute tRNA transcription using 100 ng of Mcet 1 template DNA. All other conditions as indicated in (B). The position of tRNA transcripts is
indicated.
reconstitute U6 transcription in the presence of the PC A
and B fractions and recombinant TBP. As shown in
Figure 2B, the bulk of the factor(s) required for U6
transcription fractionated into Hep500 (lanes 3-8), as did
the heat-labile Ul transcription factor (Figure ID). Note,
however, that HeplO0 supported a low level of U6
(Figure 2B, lanes 3 and 4), but not U1 (Figure 1D, lane 3)
transcription.
In order to determine whether the factor in the C fraction
behaved like TFLIC, the pol III transcription factor required
for tRNA and 5S rRNA gene transcription, we analysed the
heparin-Sepharose fractions for their content of TFIHC.
This was achieved by examining their ability to complement
the PC B fraction to allow tRNA transcription (Figure 2C).
TFHIC did not bind significantly to the heparin-Sepharose
column, but eluted into Hepl00 (lanes 3-10). This suggests
that TFIIC is not required for U6 transcription, consistent
with the data of Waldschmidt et al. (1991) who reached the
same conclusion on the basis of experiments in which TFIIC
activity was inhibited by specific oligonucleotide binding.
The same authors (Waldschmidt et al., 1991; Simmen
et al., 1992a) provided evidence that a component of the
PC C fraction essential for U6 transcription was PBP (PSE-
binding protein). PBP can be detected in the C fraction by
electrophoretic mobility shift assay using labelled promoter
DNA fragments including the mouse U6 PSE sequence as
probe [Waldschmidt et al., 1991; Figure 3A, lane 1 (the
band marked with an asterisk is not PSE-dependent and the
rapidly migrating complex is not reproducibly observed, see
below)]. Upon fractionation, PBP was mostly present in
Hep500 (Figure 3A, lanes 2-4). The specificity of the
complex for intact PSE sequences was demonstrated by
competition with unlabelled wild-type and mutant PSE
oligonucleotides (Figure 3B, lanes 2-8). When the same
oligonucleotides were added to reconstituted Ul transcription
reactions, it was found that the wild-type mouse U6 PSE
oligonucleotides were efficient competitors of specific Ul
transcription (Figure 3C, lanes 1-4) while mutant U6 PSE
oligonucleotides were not (lanes 5 and 6) suggesting that PBP
is required for Ul as well as for U6 transcription.
Additional evidence for the involvement of PBP in Ul
transcription came from an examination of the heat sensitivity
of PBP binding to the PSE in vitro. The PC C fraction was
subjected to mild heat treatment (47°C for 15 min). When
3576
the heat-treated fraction was used in an electrophoretic
mobility shift assay, the amount of detectable PBP activity
was reduced by a factor of 10 (Figure 3B, lanes 11 and 12)
while the non-specific binding activity was unaffected. Other
experiments (data not shown) confirmed that the activity of
the PBP fraction in both Ul and U6 transcription and in PSE
binding exhibited similar heat sensitivity. Together with the
results described above this implicates PBP in the
transcription of human Ul and U6 genes and, furthermore,
suggests that PBP is one essential heat-labile factor present
in the PC C fraction. Further fractionation will, however,
be required to establish whether the U1 and U6 requirements
for this fraction are completely identical and confined to PBP.
The requirements for TBP of Ul and U6 are not
identical
Having established that Ul and U6 transcription had similar
PBP requirements, we next examined their TBP
requirements. In a first experiment, we compared the ability
of various forms of recombinant TBP, in combination with
the PBP-containing HepSOO fraction, to restore Ul or U6
transcription to heat-treated nuclear extract. Full-length
recombinant human and yeast TBP and the conserved core
region (amino acids 155 -335) of human TBP were tested.
The three proteins restored AdML transcription to similar
levels when tested in the same extracts (data not shown).
Neither the Hep500 nor any of the TBP forms could support
high levels of Ul or U6 transcription alone, although as
before (Figure IC, lane 3) the PBP fraction did restore some
Ul transcription (Figure 4A and B, lanes 1-5). In
combination with the PBP fraction, however, all three forms
ofTBP allowed efficient U6 transcription, although the core
fragment also produced a high background smear of
transcription (Figure 4A, lanes 6-8). The result with the
U1 promoter was different. Here both forms of human TBP
had similar activity (Figure 4B, lanes 6 and 7). Yeast TBP,
however, did not increase Ul transcription above the level
seen with Hep500 alone (Figure 4B, lanes 2 and 8). Thus,
transcription of the Ul and U6 genes have different TBP
requirements. On their own, all forms of TBP increase read-
through transcription to some extent. This increase is
suppressed in the presence of specific transcription
(Figure 4B, lanes 6 and 7) suggesting that specific and non-
specific transcription are competitive processes.
Human U snRNA gene transcription factors
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Fig. 3. PSE oligonucleotides inhibit PBP binding and human Ul transcription. (A) Electrophoretic mobility shift analysis of PSE-binding activity.
The PC C (1 Al, lane 1) and the heparin-Sepharose fractions derived from it (1 Al each, lanes 2-4) were assayed with a promoter fragment
containing the mouse U6 PSE (see Materials and methods for details). The PBP-PSE-specific complex is indicated by an arrowhead; a non-specific
complex is indicated by an asterisk. (B) On the left panel, the specific PBP complex obtained with the heparin-Sepharose 500 mM KCl eluate
(using 1 Al of Hep500 per lane, lanes 2-8) was competed with increasing amounts (10, 50 and 100 ng) of oligonucleotides containing either a wild-
type (lanes 3-5) or a mutated (lanes 6-8) mouse U6 PSE. Lanes 1 and 2 show the mobility of the free probe and of the uncompeted complex,
respectively. On the right panel, the effect of heat-treatment (470C, 15 min) on the formation of the PBP-specific complex was determined. Lanes
9-11 are controls containing probe alone, and probe plus 1 Al of either 500 mM KCl heparin-Sepharose fraction or untreated PC C fraction,
respectively. Lane 12 contains PC C fraction heat-treated at 470C for 15 min prior to the assay. F: free probe; C: PBP-specific complex; *: a non-
specific complex. (C) Human Ul transcription is inhibited in vitro by an oligonucleotide containing the mouse U6 PSE. Aliquots (3 Al) the PC C
fraction were incubated with different amounts of the appropriate oligonucleotide for 10 min on ice and then 9 1zl of heat-treated (470C, 15 min)
HeLa nuclear extract, 2.5 ng of purified hTBP, DNA template, salts and nucleotides were immediately added. In lane 1 the preincubation was with
buffer. Lanes 2, 3 and 4 were preincubated with 10, 25 and 50 ng of a wild-type mouse U6 PSE oligonucleotide. Lanes 5 and 6 were preincubated
with 10 and 50 ng of a mutant mouse U6 PSE oligonucleotide, respectively. The position of read-through (RT) and correctly initiated (+1) hUl
transcripts is indicated. M: DNA markers. Oligonucleotides were the same as in panel B.
A TBP fraction required for human Ul transcription
The ability of the C and Hep5OO fractions to restore low-
level human Ul transcription to heat-treated extract (Figures
IC, lane 3, and 4B, lane 2) suggested that these fractions
must contain some TBP in addition to PBP. To investigate
this, it was necessary to identify components required for
U1 transcription and to devise a more direct method of
depletion of TBP from these component fractions. To
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Fig. 4. Different TBP requirements for human Ul and U6 transcription in heat-treated HeLa nuclear extracts. (A) Assay of the recombinant TBP
activities in human U6 transcription. All lanes contain 6 A1 of heat-treated (470C, 15 min) HeLa cell nuclear extract and additions as indicated:
lane 2; 3 Al of the 500 mM KCI heparin-Sepharose fraction; lanes 3-5; recombinant full-length hTBP (hTBP), human core TBP (hcTBP) and fuill-
length yeast TBP (yTBP) respectively (1 Al each, equivalent to roughly 2.5, 2 and 4 ng of hTBP, hcTBP and yTBP respectively); lanes 6-8, as for
lanes 3-5 with the addition of 3 1. of 500 mM KCl heparin-Sepharose fraction; lane 1 received buffer. All reactions were performed in the
presence of 2 ytg/ml a-amanitin. In this figure, the recovery control (RIB) is shown to help evaluate the distortion of apparent signal strength due to
the high background observed in the presence of human core TBP. The position of U6 maxigene transcripts (U6M) is indicated. (B) Assay of
recombinant TBP activities in human Ul transcription. This experiment is analogous to that in (A), except that human Ul transcription was examined
and, therefore, no a-amanitin was included in the reactions. The position of read-through (RT) and correctly initiated (+1) transcripts is indicated.
Fig. 5. Reconstitution of human Ul gene transcription after extract fractionation. (A) Reconstitution of in vitro transcription for AdML (lanes 1-5)
and hUl (lanes 6-10) was performed by combining the PC fractions (2 Al of 0.1 M; 3 /l of 0.3 M and 0.7 M; and 3 1l and 5 Al of 0.5 M for
AdML and hUl, respectively) indicated above with a + sign (a - sign indicates that a particular fraction was omitted). Correctly initiated AdML
and hUl transcripts are indicated. (B) Human Ul transcription was assayed in a combination of 0.1 M and 0.5 M fractions (lanes 1-7). Mock-
depleted fractions are indicated by a zero; TBP-depleted fractions by a - sign. Lanes 1-3 contained 3 .I of mock-depleted 0.1 M fraction together
with 10 Al mock-depleted 0.5 M fraction (lane 1) or 8 or 10 1l of TBP-depleted 0.5 M fraction (lanes 2 and 3). Lanes 4-7 contained 2 JA of TBP-depleted 0.1 M fraction together with 8 or 10 tl of mock-depleted 0.5 M fraction (lanes 4 and 5) or of TBP-depleted 0.5 M fraction (lanes 6 and
7). Lane 8 is a control using the HTFR template as a size marker (transcribed with a combination of 0.1, 0.5 and 0.7 M fractions). Correctly
initiated transcripts (hU1 + 1) and read-through transcripts (RT) from the hUl template are indicated. (C) Reconstitution of hU1 transcription in vitro.
All lanes contained 1 1,u of 0.1 M and S Al of depleted 0.5 M PC fractions. Additionally, lane 1 received buffer; lanes 2-5 received 6 1d of the
undepleted 0.5 M fraction or of the HeplOO', Hep250' or Hep5OO' fractions, respectively. Lane 6 received 3 A1 of HeplOO' and 3 dl Hep500', andlane 7, 3 Al of Hep250' and 3 IL Hep5OO'. The position of correctly initiated (+ 1) and read-through transcripts (RT) is indicated. (D) The PC 0.5
M fraction was fractionated over heparin-Sepharose and the TBP content of the different fractions analysed using a polyclonal anti-TBP antiserum.
Lanes 1-5 contain 7 Al of unfractionated nuclear extract or 100 1l of PC 0.5 M, HeplOO', Hep250' and HepS00', respectively. Lane 6 contains
recombinant human TBP as indicated.
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identify fractions necessary for Ul transcription, we adopted
a chromatographic scheme that allows more efficient
separation of the various identified TBP complexes than does
the fractionation procedure used above (see e.g. Taggart
et al., 1992). This involves step elution from PC with 0. 1,
0.3, 0.5, 0.7 and 1.0 M KCl.
The fractions obtained were first tested with an AdML
template. In the presence of the 0.1 and 0.5 M fractions,
weak transcription was observed (Figure SA, lane 1). The
0.3 M fraction was not required for AdML transcription,
and, in fact, had an inhibitory effect (lane 2). Both the 0.1
and 0.5 M fractions were essential (lanes 4 and 5). The
D-TFIID-containing 0.7 M fraction stimulated transcription
5-fold (lane 3) but was not absolutely required. The 1.0 M
fraction behaved similarly to the 0.7 M fraction (data not
shown).
In the case of human U1 transcription, combination of the
0.1 and 0.5 M fractions was again sufficient for transcription
(Figure SA, lane 6), and both these fractions were also
essential (lanes 9 and 10). However, the effects of the 0.3
and 0.7 M fractions were different than with the AdML
promoter. The 0.7 M fraction had a reproducible inhibitory
effect (lane 8 and data not shown) while the 0.3 M fraction
was stimulatory (lane 7). The 1.0 M fraction had a modest
inhibitory effect on human Ul transcription, similar to that
of the 0.7 M fraction, when combined with the 0.1 and 0.5
M fractions (data not shown).
To determine which of the two essential fractions contained
the TBP necessary for human U1 transcription, depletion
experiments were carried out with a polyclonal antiserum
raised against human TBP (Simmen et al., 1992b). The 0.1
and 0.5 M fractions were either mock-depleted (designated
0) or TBP-depleted (-) and their transcription activity tested.
Removal of TBP from the fractions was confirmed by
Western blot analysis (data not shown). Depletion of the 0.5
M fraction severely reduced transcription (Figure SB, lanes
1, 2, 3, 6 and 7) while depletion of the 0.1 M fraction had
no effect (lanes 1 and 4-7). Thus, the 0.5 M fraction
contained the TBP required for Ul transcription.
Much of the TBP in the 0.5 M fraction has been reported
to be in complexes that may be functionally different from
the active D-TFIID in the 0.7 M fraction, although their
composition is related to that of D-TFIID (Taggart et al.,
1992). To examine further the state of the TBP required for
Ul transcription, we fractionated the 0.5 M PC fraction over
heparin-Sepharose, to produce fractions analogous to those
obtained previously from the PC C fraction (Figures 1-3).
These fractions were tested for their ability to reconstitute
U1 transcription together with the 0.1 M PC fraction and
the TBP-depleted 0.5 M fraction. To distinguish these
fractions from those derived from the C fraction, we denote
them HepGOO', Hep 250' and Hep5OO'.
The activity recovered was mainly in HepSOO' (Figure 5C,
lanes 1-5), although this fraction only contained a minority
of the total TBP from the 0.5 M fraction, as judged by
Western blotting (Figure SD, lanes 1-5). Combination of
Hep500' with either Hep250' or HeplOO' failed to stimulate
transcription further (Figure 5C, lanes 5-7). The decreased
transcription level in lanes 6 and 7 was due to the fact that
they contained half as much HepSOO' as did lane 5. We
conclude that the TBP (or TBP complex) required for Ul
transcription is a minor fraction of the total TBP present in
the 0.5 M fraction and that it cofractionates with PBP on
heparin - Sepharose. U 1 transcription activity was
reproducibly lost when the 0.5 M fraction was passed over
heparin-Sepharose (e.g. Figure SC, lanes 2 and 5). In
contrast, the HepSOO fraction had a higher specific activity
than the C fraction when tested, in combination with hTBP
and the A and B PC fractions, in U6 transcription assays
(J.Lewis, unpublished data). This suggests that PBP is
probably stable to heparin-Sepharose fractionation but that
another component required for Ul transcription, perhaps
the TBP complex, is partially inactivated at this stage.
The similar heat sensitivity of TBP and PBP (see above)
suggested that the two factors might be present as a single
complex. We have, however, found no direct evidence to
support this hypothesis. In fact, TBP depletion from these
fractions or from the PC C fraction had no significant effect
on the quantity of PBP detectable by electrophoretic mobility
shift assay and addition of recombinant hTBP to heat-treated
C fraction did not restore PBP complex formation (data not
shown).
It remained possible that the TBP (complex) required for
U1 transcription was identical to one of the complexes
previously described as being competent to support pol II
transcription (D-TFIID and B-TFIID/TFLIIB, Timmers and
Sharp, 1991; Simmen et al., 1992b) fortuitously present in
the 0.5 M PC fraction as a contaminant from either the 0.7
M or the 0.3 M fraction. If this were the case, either purified
D-TFIID or B-TFIID/TFLB should be able to reconstitute
Ul transcription together with the TBP-depleted 0.5 M and
the 0.1 M PC fractions.
To test the activity of the purified TBP complexes and
to compare them with recombinant TBP and the HepSOO
fraction, we first used the AdML promoter. The amount of
D-TFIID and B-TFIID/TFIIB utilized was quantified as
follows. Recombinant human TBP and D-TFIID were
equalized for their ability to reconstitute AdML transcription
in a heat-treated extract. Then amounts of D-TFIID and
B-TFIID/TFI1IB (Mono Q fractions, see Simmen et al.,
1992b) that contained the same amount of TBP, as
determined by Western blotting, were used. Since
comparatively little TBP was present in HepSOO, we could
only add as much of this fraction as possible within the
volume constraints of the assays.
The combination of 0.1 M and TBP-depleted 0.5 M
fraction allowed background levels of AdML and Ul
transcription (Figure 6A, lanes 1 and 6). Either recombinant
human TBP or purified D-TFIID strongly stimulated AdML
transcription while the B-TFIID/TF1B fraction had weak
activity (lanes 2, 3 and 5). The HepSOO' fraction had no
effect on AdML transcription (lane 4) demonstrating that it
contained no detectable free TBP. In contrast, HepSOO' was
the only purified fraction that could stimulate Ul
transcription (lanes 8-10) although to a significantly lesser
extent than recombinant TBP (lane 7). Note, however, that
there is a considerable ( - 100-fold) difference in the amount
of TBP added in these two reactions. Both D-TFIID and the
B-TFIID/TFIIB fractions reduced human U1 transcription
to a slight extent (lanes 8 and 10), and this inhibition
increased in proportion to the amount of these fractions added
to the assay (data not shown), ruling out the possibility that
either is the essential TBP-containing complex required for
Ul transcription or that the activity of the 0.5 M fraction
is due to contamination with either of these TBP complexes.
Note that the inhibition by purified B-TFIID/TFLIB contrasts
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Fig. 6. Reconstitution of human Ul and U6 transcription in fractionated extracts with various purified TBP complexes. (A) Lanes 1-5 assayed TBPrequirements for AdML and lanes 6-10 those for hUl. All lanes received 2 ,ul of mock-depleted PC 0.1 M fraction and 6 1d of TBP-depleted PC0.5 M fraction. Additionally, lanes 1 and 6 received buffer; lanes 2 and 7 received 2.5 ng hTBP; lanes 3 and 8 received 4 Al of highly purified D-TFIID; lanes 4 and 9 received 4 yl of Hep500'; and lanes 5 and 10 received 4 Al of a Mono Q fraction containing B-TFLID/TFIIIB activity.Correctly initiated AdML and hUl transcripts are indicated. (B) Complementation assay for human U6 and tRNA genes. Lanes 1-10 contain thehU6 maxigene (100 ng) and lanes 11-14 the Mcetl tRNAP"ro gene (100 ng). Except for lanes 1 and 6, all other lanes received 3 1l of PC A and3 yd of TBP-depleted PC C (PCC-) fractions; lanes 2-5 received 1 Ad of hcTBP, and lanes 7-14 2 yd of highly purified D-TFIID. Additionally, 4ylof buffer (lanes 2, 7 and 11), PC B fraction (lanes 3, 8 and 12), DS 0.135 fraction (lanes 4, 9 and 13) and Mono Q fraction (lanes 5, 10 and 14)
were added. Lanes 1 and 6 received 10 Al of unfractionated HeLa nuclear extract. The position of hU6 maxigene and tRNA transcripts is indicated.
with the stimulation observed with the PC 0.3 M fraction
from which it is purified, indicating that a different
component of the 0.3 M fraction is stimulatory.
To compare the TBP requirement ofU1 as defined above
with that of U6, we carried out a similar experiment with
fractions required for U6 transcription. The PC A fraction
was combined with TBP-depleted PC C fraction and
recombinant TBP. No transcription was observed
(Figure 6B, lane 2), demonstrating that factors other than
TBP in the B fraction were required for U6 transcription.
The PC B fraction, and the DEAE-Sephadex (DS 0.135)
and Mono Q fractions derived from it (Simmen et al.,
1992b), were shown to contain similar amounts of TFHB
activity by their ability to complement the TBP-depleted C
fraction to reconstitute tRNA transcription (Figure 6B, lanes
11-14). These fractions were then tested for U6 activity.
In combination with recombinant human TBP the TFHB
fractions were able to generate U6 transcription in the
reconstitution experiment (Figure 6B, lanes 2-5) suggesting
that TFLIB is required for U6 transcription, consistent with
previous work (Waldschmidt et al., 1991). The Mono Q
fraction appeared significantly less active in U6 than in tRNA
transcription when compared with DS 0.135, although
reconstitution of U6 transcription with the Mono Q fraction
was readily detectable after longer autoradiographic exposure
(data not shown). Attempts to reconstitute U6 transcription
activity by the addition of other Mono Q fractions have thus
far not been successful (our unpublished data).
We wished to determine whether D-TFIID could substitute
for recombinant TBP in U6 transcription. Although the D-
TFIID fraction was highly active when tested with the AdML
promoter (Figure 6A, lane 3) it was unable, either alone or
in combination with the TFBIB fractions, to reconstitute U6
transcription (Figure 6B, lanes 6-10). This was not
attributable to a non-specific inhibitory effect of the D-TFIID
fraction on pol HI transcription, since it did not affect tRNA
transcription (Figure 6B, lanes 11-14 and data not shown).
Ul, but not U6, requires TFIIB
The discovery that a subunit of TFIIIB is highly related to
the pol II basal factor TFIIB (Buratowski and Zhou, 1992;
Colbert and Hahn, 1992; L6pez De Le6n et al., 1992) has
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led to the hypothesis that polymerase choice might occurin two steps. First a particular complex containing both TBP
and a member of the TFIIB family would form on a
promoter, and the nature of this complex would then specify
the RNA polymerase chosen [see Rigby (1993) for a review].
Since the above results suggested that U6, but not Ul,
required TFIIIB we wished to test whether the converse
would be true for TFIIB.
To determine whether TFIIB was required for U1
transcription we compared the sensitivity of Ul transcription
with that ofAdML transcription, which is known to require
TFIIB, to inhibition by monoclonal anti-TFIIB antibodies.
Transcription from both promoters was similarly inhibited(Figure 7A, lanes 1, 2, 5 and 6). Furthermore, addition of
recombinant TFIIB in similar amounts was sufficient to
restore both AdML and U1 transcription (lanes 3, 4, 7 and
8). The experiment in Figure 7A also included the addition
of 2.5 ng TBP to each reaction. Similar results were obtained
without TBP addition if 3- to 5-fold more recombinant TFIIB
was added. This demonstrates that human Ul transcription
requires TFIIB.
Addition of similar quantities of anti-TFIIB antibodies to
U6 transcription reactions had no effect (data not shown)
suggesting that TFHB was not required by U6. However,
when 50-fold more antibody was added, significantinhibition was seen (Figure 7B, lanes 1 and 2). Two facts
led us to believe that this effect was not due to TFIIB
depletion. The first was the simultaneous reduction observed
in tRNA transcription, which is thought not to require TFIIB(lane 2). The second was the failure to restore either U6 or
tRNA transcription with recombinant TFIIB (lane 3). After
examining the ability of various fractions to overcome the
inhibitory effect, we discovered that addition of recombinant
TBP, either in combination with TFIIB (lane 4) or alone
(lane 5) could fully restore both U6 and tRNA transcription.
Although we do not understand the basis of TBP depletionby the anti-TFIIB antibodies, these results strongly suggestthat TFIIB is not required for human U6 transcription.
Discussion
We have begun a biochemical investigation of factors
required for the in vitro transcription of human Ul snRNA
S.0
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Fig. 7. TFIIB is required for human Ul but not for human U6 transcription. (A) TFIIB is required for hUl transcription in vitro. All lanes contain
9 A1 of nuclear extract preincubated on ice for 10 min with either 1 I1 of a 1:40 dilution of the 2G8 anti-TFIIB monoclonal antibody (lanes 2-4 and
6-8) or buffer (lanes 1 and 5). Recombinant TFIIB [either 2 A1 (lanes 3 and 7) or 4 jA (lanes 4 and 8) salts], nucleotides and templates [either 200
ng of AdML template (lanes 1-4) or 1 1tg hUlG- (lanes 5-8)] were added. In vitro transcription was as described in Materials and methods. All
lanes received, in addition, 5 ng of recombinant human TBP. The position of correctly initiated transcripts for AdML and hUl are indicated.
(B) TFIIB is not required for transcription of a human U6 maxigene in vitro. In vitro transcription reactions were performed essentially as described
in Materials and methods, using 100 ng of a human maxigene and 7.5 ng Mcetl tRNAI'rO as templates. Before the addition of template, nucleotides
and salts, the nuclear extract (6 Al) was preincubated on ice for 10 min in the absence (lane 1) or presence (lanes 2-5) of 1 1A of undiluted
monoclonal antibodies (2G8) raised against recombinant human TFIIB. Recombinant human TFIIB (rTFIIB) or human core TBP (hcTBP) were added
(0.1 1 each; as indicated by +) just prior to the addition of template, nucleotides and salts in lanes 3-5. Sample recovery (RIB), tRNA (tRNA)
and U6 maxigene (hU6M) transcripts are indicated.
genes. Given the similarity of promoter structure exhibited
by members of the vertebrate U snRNA gene family
transcribed by pol II (e.g. Ul) and by pol III (e.g. U6), it
was of particular interest to search for similarities and
differences in their factor requirements. Both classes of
promoter appeared to utilize the same PBP, but differences
were seen in the requirements of Ul and U6 for TBP and
for TFIIB and TFIIIB. While previous studies have
emphasized similarities in factor utilization by the two
promoter classes, these are the first reported differences
which help to explain the basis of alternative polymerase
choice by the two promoters.
PSE-binding protein and U snRNA transcription
A fraction derived from HeLa cell extract required for the
transcription of a mouse U6 snRNA gene was characterized
by Waldschmidt et al. (1991). This fraction contained a
factor, named PBP, which specifically bound to the PSE of
the mouse gene. Subsequently, a correlation between the
ability of various U6 PSE sequences to activate transcription
in vitro and in vivo and to bind PBP in vitro was established
(Simmen et al., 1992a), supporting the hypothesis that PBP
was involved in U6 transcription. Parallel studies of
transcription of another human snRNA gene, that encoding
7SK RNA, led to the identification of a factor, named PSE
transcription factor (PTF), whose properties suggest that it
is likely to be identical to PBP (Murphy et al., 1992). PTF,
like PBP, was shown to bind to the PSEs of a number of
mammalian U snRNA genes in vitro, including those with
diverged sequences like that present in the human Ul gene.
Like PBP, PTF showed highest affmity for the mouse U6
PSE (Murphy et al., 1992; Simmen et al., 1992a).
Interestingly, two members of the octamer transcription
factor family, Oct 1 and Oct 2, were shown to potentiate
PTF binding to PSE sequences and the stimulation of 7SK
transcription by PTF (Murphy et al., 1992). This will be
discussed further below. For the rest of this report we will
use the PBP nomenclature.
Several lines of evidence suggest that transcription of U1,
as well as that of U6, requires PBP. First, the same PBP-
containing fraction is required for transcription of both genes.
Second, the transcriptional activity of this fraction is very
heat-labile, as is PBP binding to PSE-containing
oligonucleotides in vitro. Third, oligonucleotides containing
the mouse U6 PSE are effective competitors of both PBP
binding and of human Ul gene transcription in vitro, while
oligonucleotides containing mutant PSE sequences are not.
Fourth, when either the human or mouse U6 PSE is
introduced into the Ul promoter, or the Ul PSE into the
U6 promoter, there is no difference in polymerase specificity
or transcription efficiency between the hybrids and the
original wild-type promoters. (J.Bernues and S.Gunderson,
unpublished data). In combination, these results lead to the
conclusion that transcription of human Ul snRNA genes,
like that of U6 genes, requires PBP, although further work
will be required to determine whether the two gene classes
need additional (identical or different) components of the PBP
fraction.
Other common requirements
PBP may not be the only factor required for both Ul and
U6 transcription. It is interesting that both promoters show
an absolute requirement for the 0.1 M KCI (or A) PC
fraction. Several factors present in this fraction could provide
a plausible explanation for this. First is TFIIA. It has recently
been shown that U6 transcription in vitro requires TFIIA
or a factor with extremely similar properties (Waldschmidt
and Seifart, 1992; see also Reddy, 1988). U6 is the first
pol III gene whose transcription has been shown to require
this factor. It is, on the other hand, very plausible that pol
II transcription of U1 would, in common with many other
pol II genes (see Roeder, 1991, for a review), require TFIIA.
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A second component of this fraction which may be
required for both U1 and U6 transcription is Oct 1. As
mentioned above, Oct 1 potentiates PBP binding to PSE-
containing oligonucleotides in vitro, and the ability of PBP
to stimulate 7SK transcription (Murphy et al., 1992).
Although neither U1 nor U6 transcription in fractionated
extract is dependent upon the Oct-I-binding sites present in
the DSEs of the two promoters (our unpublished data) it may
be that Oct-I is nevertheless required for their transcription.
When the 0.1 M PC fraction was subjected to further
chromatographic steps, U6 transcription activity was found
to co-fractionate with both TFIIA and Oct 1 (J.Lewis,
unpublished data).
In contrast, a third component of the 0.1 M KCl fraction
implicated in Ul transcription, PSE-1/Ku (Gunderson et al.,
1990; Knuth et al., 1990), did not cofractionate with U6
transcription activity. In fact, the most highly purified
components derived from the A, B and C fractions that had
U6 transcription activity contained little or no PSE-1/Ku as
determined by Western blotting (S.Gunderson, J.Lewis,
K.Simmen and R.Waldschmidt, unpublished data). This,
coupled with the strong evidence implicating PBP in snRNA
gene transcription (Waldschmidt et al., 1991; Murphy et al.,
1992; Simmen et al., 1992a; this paper), makes it unlikely
that PSE-1/Ku is an essential, generally required, PSE-
binding factor. Our results, however, do not rule out the
possibility that PSE-1/Ku may play a role in U1 transcription
since the most purified fractions sufficient for Ul
transcription still contain considerable amounts of PSE-1/Ku
(unpublished data). Indeed, a general role for PSE-1/Ku in
pol II transcription has recently been proposed (Dvir et al.,
1992; Gottlieb and Jackson, 1993).
Differential TBP requirements for Ul and U6
transcription
The data presented here, together with previous studies
(Lobo et al., 1991; Simmen et al., 1991; Waldschmidt
et al., 1991) demonstrate that, as for all other eukaryotic
genes thus far examined (see Introduction) transcription of
vertebrate U snRNA genes of both classes requires TBP.
Our results suggest, however, that both have unusual TBP
requirements. The TBP (or TBP complex) required for Ul
snRNA transcription fractionates differently from the
previously identified TBP complexes involved in pol I, II
and III transcription in HeLa cell extracts [see Rigby (1993)
for a review and references] and cannot be functionally
substituted for by them (Figure 6). While TBP complexes
have previously been observed in the same PC fraction as
the Ul activity (Taggart et al., 1992), our further
fractionation on heparin-Sepharose (Figure 5) led to the
conclusion that only a minority of the TBP in the 0.5 M
PC fraction is active in U1 transcription (although we cannot
rule out the possibility that the heparin- Sepharose
chromatography resulted in a partial disruption of TBP
complexes in this fraction). The low abundance has thus far
hampered further characterization of the state of the TBP
in the active fraction, but larger scale experiments should
resolve this point. The nature of this complex is of particular
interest since human Ul is the first genuine TATA-less pol
II promoter whose transcription factor requirements have
been examined, previous experiments with TATA-less
promoters all having been carried out with artificial
constructs that, unlike Ul, require D-TFIID-containing
fractions for their transcription (Smale et al., 1990; Pugh
and Tjian, 1990, 1991; Zhou et al., 1992). With regard to
this point it is of interest that the changes made to the Dignam
et al. (1983) protocol that led to increased efficiency of Ul
gene transcription (see Materials and methods) led to a drop
in the efficiency of AdML transcription (J.Bernuds,
unpublished data). In parallel, we noted that comparatively
little TFIID activity or TBP protein was present in the D
fraction of the extracts optimized for Ul activity. This,
together with the inhibitory effect of D-TFIID in the
reconstitution experiments (Figure 6A), suggests that
D-TFIID may compete with the TBP complex active in Ul
transcription and thus have a negative effect on human U1
promoter activity.
Our results show that U6 transcription has different TBP
requirements from Ul. First, yeast TBP is capable of
restoring U6 transcription activity to heat-treated HeLa cell
extracts, but is incapable of restoring Ul transcription,
suggesting that TBP has to interact with different components
of the extract when involved in transcription from the two
promoters. (Note that these experiments are all carried out
in conditions where deletion of the enhancer-like DSE from
the U1 or U6 promoter has no effect on transcription
efficiency, and thus basal promoter activity was measured.)
The second line of evidence is that U6 and Ul transcription
in vitro require different TBP-containing fractions.
U6 transcription requires TFIIIB-containing fractions
(Waldschmidt et al., 1991; Figure 6B), as well as,
apparently, a second component of the PC B fraction not
required for tRNA transcription. This can be deduced from
the differential loss of U6 and tRNA transcriptional activity
upon Mono Q fractionation of TFIIB activity (Figure 6).
TFIIB is a TBP-containing complex (Huet and Sentenac,
1992; Kassavetis et al., 1992; Lobo et al., 1992; Simmen
et al., 1992; Taggart et al., 1992; White and Jackson, 1992).
However, TFIHB fractions alone are insufficient to fulfil the
TBP requirement of the U6 gene. After fractionation, TBP
addition was essential to obtain efficient transcription,
suggesting that fractionation had disrupted or destroyed an
essential component of the U6 transcription machinery which
could be substituted by recombinant TBP. This alone would
suggest that the U6 TBP requirement is different from that
of other previously studied genes, since other promoters that
show such behaviour have not been described. Together with
the TFIB requirement, it furthermore suggests that U6
transcription involves more than one TBP molecule, and
possibly more than a single TBP complex. It has previously
been reported that D-TFIID-containing fractions can
substitute for TBP in restoring U6 transcription in
fractionated systems, albeit with very low efficiency
(Waldschmidt et al., 1991; Lobo et al., 1992). However,
highly purified D-TFIID does not have this ability
(Figure 6B). We would suggest that the previous results may
be explained by the presence of small quantities of free TBP
in the crude D-TFIID fractions, and conclude that either free
TBP or an unstable TBP complex is involved in U6
transcription.
Polymerase choice
Previous work has suggested that U6 transcription requires
TFIIA (Waldschmidt and Seifart, 1992). The differential
requirements of Ul and U6 transcription for TFIIB and
TFLIIB described here are the first examples of dissimilar
3582
Human U snRNA gene transcription factors
requirements for basal factors in the transcription of these
genes. We propose the following model for the differential
ability of the promoters to attract TBP complexes. The only
DNA sequence absolutely required for basal vertebrate pol
II U snRNA gene transcription is the PSE (reviewed by
Dahlberg and Lund, 1988; Parry et al., 1989; Bernues et al.,
1992). PBP bound to the PSE, perhaps in combination with
TFIIA and/or Oct 1 or other members of the Oct family
(Murphy et al., 1992) would bind to the form of TBP
identified here as being necessary for U1 transcription,
possibly via a tethering factor or TFII-I (see Pugh and Tjian,
1990, 1991; Roeder, 1991). This complex would then attract
TFIIB and, from that point, pol II transcription complex
assembly could follow its conventional route (reviewed by
Roeder, 1991). In contrast, we would propose that PBP and
either free TBP or an unstable TBP complex would interact
with the PSE and TATA sequences of the U6 promoter
respectively. The combination of these factors, again
probably in conjunction with Oct 1 and TFIIA, would act
as assembly factors for the pol III transcription factor,
TFJIB. These factors would thus be functionally analogous
to TFIIIC in tRNA, or to TFIHA plus TFIIIC in 5S rRNA
transcription (Kassavetis et al., 1990). In this model, the
ability of the two classes of U snRNA promoter to select
different polymerases would be explicable by their interaction
with alternative TBP complexes, just as has been previously
proposed for other pol l, II and HI promoters (see Rigby,
1993, for review) whose structures are much more obviously
different from one another than are those of the human U1
and U6 genes.
Materials and methods
Nuclear extract preparation and fractionation
HeLa cell nuclear extracts were prepared as described by Dignam et al.
(1983) except that a reduced volume of buffer C was used in the extraction
step. The amount of buffer C used corresponded to one-third of the packed
cell volume. For pol HI transcription studies the extracts were fractionated
over PC (Whatman P11) into four fractions according to Segall et al. (1980).
The protein concentration of the fractions used here were PC A (100 mM
flowthrough, 4 mg/ml protein), PC B (at 0.35 M KCl, 2 mg/ml protein),
PC C (at 0.6 M KC1, 0.9 mg/ml protein) and PC D (at 1 M KCI, 0.7 mg/ml
protein). Similar concentrations were obtained from repeated fractionations.
PC C fraction (containing PBP activity) was further fractionated over
heparin-Sepharose and fractions were collected at 100, 250 and 500 mM
KC1. The protein concentration of the heparin-Sepharose fractions used
were 0.25, 0.4 and 0.9 mg/ml respectively. PC B fraction was further
fractionated over DEAE-Sephadex and subsequently over Mono Q as recently
described (Simmen et al., 1992b). All fractions were extensively dialysed
against buffer D (100 mM KCl, 0.2 mM EDTA, 20% glycerol, 0.5 mM
DTT, 20mM HEPES, pH 7.9, 0.1 mM PMSF) and stored at -800C until
use.
For pol II transcription studies nuclear extracts were fractionated over
PC (Whatman P11) essentially as described by Reinberg and Roeder (1987).
The fractions utilized in the experiments shown were collected at 0.1 M
(4 mg/mi protein), 0.3 M (2.9 mg/ml protein), 0.5 M (2.3 mg/ml protein),
0.7 M (0.83 mg/ml protein) and 1.0 M KCl (0.29 mg/mi protein). Similar
concentrations were obtained in several fractionations. Fraction PC 0.5 M
was further fractionated over heparin- Sepharose exactly as described above
for the PC C fraction. All fractions were extensively dialysed against buffer
D (100 mM KCl, 0.2 mM EDTA, 20% glycerol, 0.5 mM DTT, 20 mM
HEPES, pH 7.9, 0.1 mM PMSF) and stored at -80°C until use.
DNA templates and expression constructs
For pol II transcription the templates used were: AdML404[180] G- and
AdML50[180] G- (interchangeably used as AdML; Simmen et al., 1991),
HTFR G- and hUl G- (Gunderson et al., 1990).
For pol IH transcription the templates were a human U6 maxigene
(hU6RVM, Simmen et al., 1991) and a ntmatode tRNAPrO gene (Mcetl,
Ciliberto et al., 1982).
The expression plasmid containing the full-length human TBP cDNA
6 x His-tagged at the N-terminus was provided by A.Hoffmann and R.Roeder
(The Rockefeller University, New York). The human TBP core plasmid
was obtained by subcloning a 6xHis-tagged C-terminal fragment coding
for amino acids 155 -335 into the pET vector (provided by A.Berkenstam
and H.Stunnenberg, EMBL, Heidelberg). The yeast TBP expression
construct used was described by Burton et al. (1991): The human TFIIB
expression plasmid (Ha et al., 1991) was a gift of D.Reinberg.
In vitro transcription
Pol II reactions were in a final volume of 25 1l and contained 3.5 mM
MgCl2, 1.2 mM 3'-O-methyl-GTP (Pharmacia), 0.4 mM ATP, 0.4 mM
CTP, 2 units RNase TI, 1.25 mM DTT, 2% polyethylene glycol 8000
(Sigma), 0.2 mM EDTA, 20 1Ci [ci-32P]UTP (800 Ci/mmol), 33 mM
HEPES, pH 7.9 and nuclear extract equivalent to 150-170 Ag of protein.
For in vitro reconstitution experiments fractions were used as described in
each case. MgCl2 concentration was always adjusted to 5 mM for AdML
transcription.
DNA templates were used at 1 Ag (hUl G-), 0.2 jig (AdML) and 0.35 jg
(HTFR G-) per reaction. Transcription was allowed to proceed for
60-90 min at 30°C and samples were processed as described by Gunderson
et al. (1990). In all cases an unrelated riboprobe was added after the
transcription reaction was completed as a recovery control. Transcripts were
analysed on 8% denaturing poylacrylamide gels, dried and exposed to X-
ray sensitive film (Kodak) at -80°C with intensifying screens.
Mapping of start sites by primer extension used an oligonucleotide
complementary to sequences between +59 and +41 in the human U1 and
HTFR G- cassettes. The same oligonucleotide was complementary to +64
to +46 of the AdML G- cassette used. Conditions-for primer extension
were exactly as in Gunderson et al. (1990). Pol mII transcription conditions
were as described by Simmen et al. (1991) except that PC A, B and C
fractions prepared as described above were used.
TBP-immunodepletion of PC fractions and immunoblot analysis
The fractions, as described in the text, were TBP-immunodepleted with
a rabbit polyclonal anti-hTBP antibody prepared and used as described in
Simmen et al. (1992b). Mock-depletion was performed in exactly the same
way but using preimmune serum. The presence of TBP in fractions was
assayed using 100 A1 of the indicated fractions with the ECL system
(Amersham) for Western blotting (Simmen et al., 1992b).
Gel retardation assays
Gel retardation assays were performed usin' conditions modified from those
described by Fried and Crothers (1981). The protein fractions were pre-
incubated with 600 ng poly[d(IC)] in 1 x binding buffer (5% Ficoll, 100
mM KCI, 20 mM Tris-HC1, pH 8, 1 mM DTT) at 30°C for 30 min.
Then 20 000 c.p.m. of a kinased probe was added and incubation continued
for a further 30 min. DNA-protein complexes were then resolved on a
6% non-denaturing polyacrylamide gel in 0.5 x TBE. The probe contained
the mouse U6 gene promoter sequences from -80 to -4 (Ohshima et al.,
1981) and was excised from a PCR-generated derivative of the mouse U6
gene. The sequences of the two oligonucleotides used for the competition
experiments are given below.
WT:
ACAAAAGGAAACTCACCCTAACTGTAAAGTAATTGTGTGTT
TGTTTTCCTTTGAGTGGGATTGACATTTCATTAACACACAA
MT:
ACAAAAGGAAACTAAGATCTGCTGTAAAGTAATTGTGTGTT
TGTTTTCCTTTGATTCTAGACGACATTTCATTAACACACAA
TBP overexpression and purification
Overexpression of the full-length and core human TBP proteins was as
follows: Escherichia coli BL21 (LysE) transformants were grown in
Superbroth, supplemented with 4% glucose, 25 Ag/ml chloramphenicol and
100 Ag/ml ampicillin, at 30°C until the OD6W was -0.7. At that point
IPTG was added to 0.5 mM and cultures were grown for another 2 h at
30°C. Cells were then harvested by centrifugation, washed and lysed with
30 ml of lysis buffer (0.5 M NaCl, 20% glycerol, 1 mM EDTA, 20 mM
2-mercaptoethanol, 20 mM HEPES, pH 7.9, 0.1% NP40, 1 mM PMSF,
20 tg/ml pepstatin A, 20 14g/mn leupeptin, 1% aprotinin) per litre of culture
by extensive sonication on ice. Cell debris were pelleted by ultracentrifugation
(100 000 g, 4°C, 1 h) and the supernatant was further clarified by passing
through a DEAE-Sephadex A-25 column equilibrated in the same buffer.
The flow-through was collected and applied to a 0.5-1 ml Ni2+-NTA
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column (Diagen) equilibrated in lysis buffer. After loading, the resin was
extensively washed, first with lysis buffer followed by D buffer and finally
eluted with 3-5 vol of D buffer containing 100 mM imidazole. Active
fractions were pooled, aliquoted, frozen in liquid N2 and stored at -80°C.
Recombinant yeast TBP was expressed in E. coli and purified as described
in Burton et al. (1991).
TFIIB
Recombinant TFIIB was expressed in E. coli and purified as described (Ha
et al., 1991). The 2G8 monoclonal anti-TFIIB antibody (V.Moncollin,
unpublished data) was purified as follows. 1 ml ascites fluid was diluted
1:10 with phosphate-buffered saline (PBS) and passed over a protein
A-Sepharose column. The column was washed with 100 ml of PBS then
eluted with 0.05 M sodium acetate, pH 4. Fractions (1.5 ml) were neutralized
with 750 1l 1 M Tris-HCI pH 8.0 and dialysed against buffer C (see D-
TFIID purification section) before use.
Endogenous D-TFIID purification
D-TFIID was purified from HeLa whole cell extract by sequential
chromatography on Heparin-Ultrogel and DEAE-5PW (Moncollin et al.,
1986) followed by hydrophobic and DNA-affinity chromatography as
described below. The DEAE 0.25 M KCI active fractions were pooled,
adjusted to 0.9 M (NH4)2SO4 with solid ammonium sulphate and loaded
onto a TSK-Phenyl-SPW column (2.15 cm x 15 cm, flow-rate 2.5 nl/min)
equilibrated with buffer A [59 mM Tris-HCl, pH 7.9, 50 mM KCI, 0.5
mM DTT, 0.1 mM EDTA, 8.7% glycerol and 0.9 M (NH4)2 S04]. After
washing with buffer A, the proteins were eluted with a 250 ml linear gradient
from 0.9 to 0 M (NH4)2SO4 in buffer A. The active fractions, eluted at
0.2 M (NH4)2SO4, were pooled (50 ml) and dialysed against buffer B (50
mM Tris-HCl, pH 7.9, 50 mM KC1, 17.5% glycerol, 5 mM MgCl2,
0.1 % Nonidet P-40, 1 mM DTT). This fraction was then incubated at 4°C
for 15 min with 100 yg/ml of poly(dG-dC) and 5 mM MgCl2. 2 ml of
TATA-containing DNA affinity resin (Moncollin et al., 1990) were added
and the incubation continued for 15 min. The resin was then packed and
washed with 10 column volumes of buffer B. Proteins were eluted in fractions
of 1 ml with buffer B containing increasing concentrations of KCI (in
irements of 0.1 M). The D-TFJID-containing frcions (eluted at 0.4-0.5 M
KCI) were dialysed against buffer C (50 mM Tris-HCI, pH 7.9, 50 mM
KCI, 17.5% glycerol, 0.1 mM EDTA, 0.5 mM DTT) and stored at -800C.
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